Forendo Pharma Ltd

Solvay Pharmaceuticals, Gmbh

Hormos Medical Corporation

Solvay Pharmaceuticals, B.v.

Hormos Nutraceutical Oy Ltd.

Mikko Unkila

Lauri V Kangas

Pasi Koskimies

Risto A Lammintausta

Leena Hirvelä

Josef Messinger

Markku Ahotupa

Maire Eloranta

Heinrich-Hubert Thole

Bettina Husen

Helena Korte

Mervi Hiilovaara-Teijo

Uwe Schoen

Arja Marketta Kalapudas

John E Eriksson

Veli-Matti Lehtola

Nina Johansson

Lila Pirkkala

Mark Stuart Johnson

Tiina Annamaria Salminen

Pekka Lehtovuori

Tommi Nyroenen

Olli Taneli Pentikaeinen

Leena Hirvelae

Marja Södervall

Patrik Eklund

Bartholomeus Johannes Van Steen

Anna Lindholm

Merja Perälä

Janne Komi

Johanna Kiviniemi

Pauli Saarenketo

Rainer Sjohölm

Leena HirvelÄ

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.

Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17&#x3b2;-hydroxysteroid dehydrogenase

Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17&#x3b2;-hydroxysteroid dehydrogenase (17&#x3b2;-HSD) type 1, type 2 and/or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for preparing such compounds. 

Substituted estratriene derivatives as 17BETA HSD inhibitors

A topical formulation which includes a lignan or lignan ester in a dermatologically acceptable vehicle. The formulation can be either a cosmetic formulation or a pharmaceutical formulation.

Lignan formulations

Novel phenolic esters of lignans, and pharmaceutical compositions, dietary supplements, and food products containing these esters.

Lignan derivatives

Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17&#x3b2;-hydroxysteroid dehydrogenase enzymes.

Compounds and their use in therapy

The invention relates to a method of inhibiting myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan, where said lignan is enterolactone. The invention is further directed to a method inhibiting myeloperoxidase activity or oxidative burst of macrophages in an individual by administering to the individual an effective amount of a lignan where said lignan is enterolactone or hydroxymatairesinol or a mixture. Finally, the invention is directed to a method of inhibiting oxidative burst or myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan which is hydroxymatairesinol.

Method of inhibiting overactivity of phagocytes or lymphocytes in an individual

Growing community of inventors

Piikkiö, Finland

Mikko Unkila